Prime Medicine (NASDAQ:PRME) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Prime Medicine (NASDAQ:PRME – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $8.00 price target on the stock. HC Wainwright‘s target price suggests a potential upside of 87.35% from the company’s current price.

PRME has been the topic of several other reports. Jefferies Financial Group reaffirmed a “market outperform” rating on shares of Prime Medicine in a research note on Monday, September 28th. Weiss Ratings reissued a “sell (e+)” rating on shares of Prime Medicine in a research report on Monday, August 31st. Wall Street Zen upgraded shares of Prime Medicine from a “sell” rating to a “hold” rating in a research note on Saturday, October 31st. Citigroup restated a “market outperform” rating on shares of Prime Medicine in a research note on Friday, September 25th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $7.00 price objective on shares of Prime Medicine in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.86.

View Our Latest Stock Analysis on Prime Medicine

Prime Medicine Stock Performance

Shares of PRME opened at $4.27 on Monday. The stock has a market capitalization of $774.49 million, a PE ratio of -4.45 and a beta of 2.13. Prime Medicine has a 1 year low of $2.67 and a 1 year high of $5.91. The company’s 50-day simple moving average is $3.70 and its 200-day simple moving average is $3.51.

Prime Medicine (NASDAQ:PRME – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. The business had revenue of $4.21 million during the quarter. Prime Medicine had a negative net margin of 2,497.56% and a negative return on equity of 222.88%. On average, sell-side analysts predict that Prime Medicine will post -0.97 earnings per share for the current year.

Hedge Funds Weigh In On Prime Medicine

A number of institutional investors and hedge funds have recently made changes to their positions in PRME. Arizona State Retirement System increased its holdings in shares of Prime Medicine by 15.5% in the 2nd quarter. Arizona State Retirement System now owns 28,646 shares of the company’s stock valued at $106,000 after acquiring an additional 3,855 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Prime Medicine by 15.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 33,094 shares of the company’s stock worth $102,000 after purchasing an additional 4,349 shares during the last quarter. Royal Bank of Canada boosted its holdings in Prime Medicine by 89.3% in the first quarter. Royal Bank of Canada now owns 9,254 shares of the company’s stock valued at $32,000 after purchasing an additional 4,365 shares in the last quarter. Swiss National Bank boosted its holdings in Prime Medicine by 5.0% in the first quarter. Swiss National Bank now owns 178,600 shares of the company’s stock valued at $622,000 after purchasing an additional 8,500 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new position in Prime Medicine in the third quarter valued at approximately $28,000. 70.37% of the stock is owned by institutional investors and hedge funds.

Prime Medicine Company Profile

(Get Free Report)

Prime Medicine is a biotechnology company developing genetic therapies for diseases caused by genetic mutations. Its research focuses on prime editing, a gene-editing technology designed to make targeted changes to DNA, including substitutions, insertions and deletions. The company is working to apply its platform to potential treatments for a range of serious conditions. Its programs are in development, and Prime Medicine does not currently market approved therapies. Founded in 2019, Prime Medicine is based in Cambridge, Massachusetts.

See Also

Analyst Recommendations for Prime Medicine (NASDAQ:PRME)

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.